Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents

Designed ligands of G protein-coupled receptors can exert a spectrum of modulating effects, varying from full agonists and partial agonists to antagonists and inverse agonists. For the dopamine D2 receptor (D2R), partial agonist activity is the pharmacological feature of the third-generation antipsychotics, including aripiprazole, brexpiprazole, and cariprazine. Started from a benzofuran-derived D2R full agonist O4LE6 (4), which was identified using a structure-based method by us in previous studies, a series of D2R partial agonists were designed and synthesized by introducing different tail groups. Among them, compound 10b showed excellent activity in D2R pharmacological assays. Further optimizations using a structural rigidification approach led to the discovery of brain-penetrant compounds 29c and 29d, which exhibited potent antipsychotic effects in the mouse hyperlocomotion model. Compound 29c also showed excellent drug-like pharmacokinetic properties in rats and qualifies as an antipsychotic agent that is worth further evaluations.

Automated summary

Designed ligands of G protein-coupled receptors can have various modulating effects, including full agonist, partial agonist, antagonist, and inverse agonist. Partial agonist activity is the pharmacological feature of third-generation antipsychotics for the dopamine D2 receptor (D2R). A series of D2R partial agonists were designed and synthesized based on a benzofuran-derived D2R full agonist. Compound 10b showed excellent activity, and further optimizations led to the discovery of brain-penetrant compounds 29c and 29d with potent antipsychotic effects.